- Home
- PVL vs PMVP Comparison
PVL vs PMVP Comparison
Compare PVL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | PMVP |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 66.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PVL | PMVP |
|---|---|---|
| Price | $1.76 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 91.6K | ★ 253.0K |
| Earning Date | 03-20-2026 | 03-02-2026 |
| Dividend Yield | ★ 10.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $3,511,891.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.32 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $0.81 |
| 52 Week High | $2.04 | $1.84 |
Technical Indicators
Market Signals| Indicator | PVL | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 50.45 | 46.95 |
| Support Level | $1.73 | $1.05 |
| Resistance Level | $1.84 | $1.19 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 41.18 | 54.76 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.